EE162 Healthcare Resource Utilization and 2022 Cost Update of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel (IDE-CEL, BB2121) in KarMMa
Abstract
Authors
N. McGarvey K. Imanak T. Carattini B. Ung T.B. Campbell M. Gitlin P. Patwardhan